Physician profile
Bethany L Mitchell
NPI 1952696874
$2,687.83
in general payments reported to CMS, 2019-2025
24 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $135 · 2024: $1,094 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,687.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $381.49 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $372.87 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $295.76 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $295.63 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $262.92 | 2023-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $248.25 | 2024-2025 | Veozah |
| Amgen INC. | $205.92 | 2023-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.53 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Merck Sharp & Dohme LLC | $69.37 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Daiichi Sankyo INC. | $58.18 | 2024-2025 | Injectafer |
| Exact Sciences Corporation | $53.11 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $44.91 | 2025 | |
| Phadia US INC. | $37.86 | 2024 | Immunocap |
| Csl Behring | $33.47 | 2025 | Haegarda |
| Phathom Pharmaceuticals, INC. | $32.78 | 2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.71 | 2025 | Caplyta |
| Cranial Technologies, INC | $25.42 | 2025 | Doc Band |
| Amneal Pharmaceuticals LLC | $25.32 | 2024 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $22.01 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $21.59 | 2025 | Neffy |
| Ardelyx, INC. | $21.42 | 2024 | Ibsrela |
| Janssen Pharmaceuticals, INC | $19.85 | 2024 | Spravato |
| Electromed, INC. | $17.98 | 2025 | Smartvest |
| Kowa Pharmaceuticals America, INC. | $17.48 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.